EX-23 5 ex23.htm

 

Consent of Independent Registered Public Accounting Firm

 

The Board of Directors and Shareholders

Antares Pharma, Inc.:

 

We consent to the incorporation by reference in this Registration Statement on Form S-3 of Antares Pharma, Inc. of our report dated March 24, 2009, relating to the consolidated balance sheets of Antares Pharma, Inc. and subsidiaries as of December 31, 2008 and 2007, and the related consolidated statements of operations, stockholders’ equity and comprehensive loss, and cash flows for each of the fiscal years in the three-year period ended December 31, 2008, which report is included in the March 25, 2009 annual report on Form 10-K of Antares Pharma, Inc. and to the reference to our firm under the heading “Experts” in the prospectus.

Our report dated March 24, 2009 contains an explanatory paragraph that states that the Company has incurred recurring losses and negative cash flows from operations since inception. Additional revenue arrangements or financing may be needed to enable the Company to fund the Company’s future operations, which raises substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.

 

/s/ KPMG, LLP

 

Minneapolis, Minnesota

April 17, 2009